Search

This review provides a brief overview of the current state of systemic antifungal therapy. Currently licensed drugs, including amphotericin B ant its lipid derivates: 5-fluorocytosine; the azoles, including fluconozole, itraconazole, and voriconazole; and a representative of the new class of echinocandin (micafungin and anidulafungin) that are likely to be licensed in the United States in the next years are also addressed. The antifungal spectra of each agent are presented on table 1, and recommended dosages are summarized on table 2. [ABSTRACT FROM AUTHOR]

The article presents antiviral agents in use for the treatment of HBV and HCV [interferon (HBV and HCV), lamivudine (HBV), adefovir (HBV) and ribavirin in combination with interferon (HCV)] and antiviral agents in use for HPV infection, the most prevalent for sexually transmitted diseases, with 75% of women in USA acquiring genital HPV infection at some point in their lives. [ABSTRACT FROM AUTHOR]